Abstract The chemotherapeutic agent doxorubicin (DOX) has significantly increased survival rates of pediatric and adult cancer patients. However, 10% of pediatric cancer survivors will 10-20 years later develop severe dilated cardiomyopathy (DCM), whereby the exact molecular mechanisms of disease progression after this long latency time remain puzzling. We here revisit the hypothesis that elevated apoptosis signaling or its increased likelihood after DOX exposure can lead to an impairment of cardiac function and cause a cardiac dilation. Based on recent literature evidence, we first argue why a dilated phenotype can occur when little apoptosis is detected. We then review findings suggesting that mature cardiomyocytes are protected against DOX-induced apoptosis downstream, but not upstream of mitochondrial outer membrane permeabilisation (MOMP). This lack of MOMP induction is proposed to alter the metabolic phenotype, induce hypertrophic remodeling, and lead to functional cardiac impairment even in the absence of cardiomyocyte apoptosis. We discuss findings that DOX exposure can lead to increased sensitivity to further cardiomyocyte apoptosis, which may cause a gradual loss in cardiomyocytes over time and a compensatory hypertrophic remodeling after treatment, potentially explaining the long lag time in disease onset. We finally note similarities between DOX-exposed cardiomyocytes and apoptosis-primed cancer cells and propose computational system biology as a tool to predict patient individual DOX doses. In conclusion, combining recent findings in rodent hearts and cardiomyocytes exposed to DOX with insights from apoptosis signal transduction allowed us to obtain a molecularly deeper insight in this delayed and still enigmatic pathology of DCM.
Introduction
Doxorubicin (DOX) is a widely and successfully applied chemotherapeutic [1] [2] [3] which has increased the 5-year survival rates for pediatric cancer patients from 58 to 80% within the last 20 years [4] . However, DOX clinical utility and dosage regimens are often limited by severe acute, sub-acute, or chronic side effects [5] . While acute and sub-acute toxicity are rare (1-4%) and can be managed by adaptation of dosage regimens during, or cessation of, treatment, chronic side effects occur often several years after treatment [6] .
The most severe chronic side effect of DOX is chronic dilated cardiomyopathy (DCM). Chronic DCM leads to cardiac dysfunction and eventually congestive heart failure, resulting in the need for heart transplant or even causing death [7] . Chronic DCM occurs in about 10-20% of cancer survivors often 10-15 years following treatment [3, 8, 9] . As the likelihood of DCM cannot be assessed a priori for an individual patient, the usual dosage of DOX is usually restricted to 60-75 mg/m 2 every 3 weeks, hence limiting its efficacy [10] . The late onset of DCM symptoms after cessation of treatment suggests the presence of a slow maladaptive remodeling after initial DOX exposure. Therefore, to understand and mitigate DOX-induced chronic DCM, several excellent reviews have focused on the effect of DOX-deregulated oxidative metabolism [11, 12] , DOX-induced autophagy [13] , or on the broader clinical scope of DOX-induced DCM [14] . We here focus on the role of apoptosis to discuss potential molecular underpinnings of a chronic DCM phenotype, paying specific attention to apoptosis alteration after cardiomyocyte differentiation and DOX exposure.
Evidence for cardiomyocyte apoptosis in DOX-induced DCM
Apoptosis may contribute to DOX-induced DCM and heart failure [12, [15] [16] [17] either by acute apoptotic damage of cardiomyocytes or by mechanisms that increase their future apoptosis likelihood. However, the relevance of apoptosis in DOX-induced DCM is often questioned as the amount of apoptosis in biopsies from patients or from heart transplants following DCM is low compared to necrotic cell death [18, 19] . A suggested reason for the low amount of apoptosis detected in DCM is that apoptosis gradually evolves over time, initiating a slow mechanism of cardiomyocyte hypertrophy over years to replace cardiomyocyte loss [20] . Further, apoptosis is often overshadowed by the presence of secondary necrosis. Secondary necrosis follows the original apoptotic cell death when scavengers of apoptotic debris such as phagocytes operate insufficiently [21] or when ATP levels are too low for robust apoptosis execution [22] , both of which are conditions typical in the impaired and failing heart [23] .
Indeed, despite the low detectable amount of apoptosis, several studies suggest it plays a functional role in DCM. In one study, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining of heart tissue from 21 transplant patients with DCM revealed 0.119% TUNEL positive cardiomyocytes, indicative of apoptosis. While low, this amount was higher than in patients with ischemic heart disease (0.075%) and in control patients (<0.002%), and the amount of cardiomyocytes apoptosis positively correlated with disease progression [24] . Moreover, in a transgenic mouse model with constitutively active caspase-8, only a small detectable elevation of apoptosis 23 myocytes per 10 5 cells sufficed to induce a dilated cardiomyopathy phenotype [25] . Importantly, this amount is four-to tenfold lower than that measured in three independent studies of failing human hearts. Further, mechanistic support for a role of cardiomyocyte apoptosis in the development of a dilated phenotype following DOX exposure comes from Zhang and colleagues [26] . The authors linked the cardiac specific isoform of the canonical target of DOX-induced apoptosis, topisomerase 2β (TOP-2β) to a DCM phenotype. Using a tetracyclineinducible mouse model of TOP-2β-deletion specific to the heart, the authors found apoptosis to be elevated in TOP-2β wild-type mice after DOX treatment, but not in mice where TOP-2β was conditionally deleted. Also, DOX treatment of TOP-2β wild-type mice showed increased left-ventricular end-systolic volume (LVESV), increased diastolic volume (LVEDV), and reduced cardiac ejection fraction (EF). Importantly, these detrimental effects were ablated after DOX exposure in mice with TOP-2β-deletion.
Pathways of cardiomyocyte apoptosis relevant to DOX-induced DCM
Firstly, we describe DOX-induced caspase-dependent apoptosis in cancer cells and subsequently discuss evidence of the molecular mechanisms so far being confirmed in cardiomyocytes ( [27] , Fig. 1 ). We further note that other proteases [28, 29] , metabolic dysfunction or autophagocytic processes [13] may also play a role in regulating cardiomyocyte demise, specifically when canonical caspase activation is blocked or initial injury is too severe [15] .
During cancer treatment, DOX firstly intercalates with cellular DNA leading to trapping of topoisomerase 2 (TOP2), an enzyme that regulates the unfolding of the DNA during replication. Inhibition of TOP2 induces genotoxic stress and the activation of p53 [26, 30] . Transcriptional activity of p53 biases the levels of pro-and anti-apoptotic proteins of the BCL2 family towards the prior by inducing expression of BCL2 family proteins PUMA and NOXA (Fig. 1a) , leading to the process of mitochondrial outer membrane permeabilisation (MOMP; Fig. 1b) . MOMP leads to the release of further apoptotic proteins, which initiates the downstream apoptosis program, and culminates in caspase activation and cell death (Fig. 1c) . Besides this genotoxic stress-induced, intrinsic pathway of apoptosis, an extrinsic path may also be evoked by binding of cell death ligands such as Fas ligand (FAS-L) to their receptor (Fig. 1d) . In this case, caspase-3 is activated either by a positive feedback loop with upstream caspase-8 (so-called type I cells) or after MOMP which is mediated by of the BCL-2 protein BID (type II cells). MOMP further induces an energetic crisis caused by the loss of cytochrome c, which may lead to necrosis or metabolic impairment when caspase-dependent apoptosis is blocked [22, 31, 32] .
The above study of Zhang [33] suggests that cardiomyocyte apoptosis after DOX treatment parallels the discussed p53-dependent genotoxic stress mechanism from cancer cells by targeting the cardiac specific TOP-2β isoform. Indeed, p53-dependency was further suggested by investigating DOXinduced DCM in a mouse model with conditional knock out of the p53-inhibitor MDM4 under the presence of p53-null and p53-competent alleles [34] . A potential role of the p53 target PUMA, commonly known to be upregulated after genotoxic stress in cancer cells [35] , has also been suggested to be relevant for cardiomyocyte apoptosis in response to DOX as observed for H9C2 cardiomyoblasts [36] . A similar PUMA-dependency of cardiomyocyte apoptosis has been found in ischemia- . This upregulation changes the balance of pro-and anti-apoptotic BCL-2 protein family members towards the prior and culminates in the activation of BAK and BAX to form pores in the mitochondrial outer membrane, leading to MOMP. b During MOMP, the pro-apoptotic protein cytochrome c and SMAC are released. c Downstream apoptosis after MOMP is mediated by the apoptosome-dependent activation of caspase-9 and caspase-3 leading to cell death. Downstream apoptosis is negatively and positively regulated by XIAP and SMAC, respectively. The likelihood of downstream apoptosis was suggested to be reduced after differentiation [41, 47] and increased after cardiomyocytes have been exposed by DOX before [26] . d Extrinsic apoptosis is mediated by cell death ligands such as FAS-L binding to their receptor. This binding leads to a conformational change of the cytosolic moiety of the receptor, recruiting the adaptor protein FADD and caspase-8. Caspase-8 gets auto-activated by proximity and this process is regulated by long and short isoforms of FLIP. In type I cells, robust caspase-3 activation is initiated its activation and due to a positive feedback with caspase-8. In type II cells, MOMP is further initiated by caspase-8 mediated cleavage and activation of the BCL-2 family protein BID. Cardiomyocytes have been shown to release FAS-L after DOX [42] while getting also sensitized to it after DOX exposure [50] . e Due to the absence of cytochrome c in the mitochondrial intermembrane space, MOMP can lead to a bioenergetics crisis with loss of mitochondrial polarization, reduced ATP production, and failure of ionic homeostasis. This mechanism may lead to necrosis or a maladaptive metabolic phenotype rendering cardiomyocytes less functional [31, 63] reperfusion model of cultured cardiomyocyte [37] . This pathway would also involve BCL2-protein interaction [38, 39] , BAX/ BAK-induced MOMP [40] , and activation of initiator and activator caspases [25, 40, 41 ] similar to the above-presented canonical intrinsic apoptosis in cancer cells. Likewise, invocation of the extrinsic apoptosis program by DOX via FAS-L or TNF-related apoptosis-inducing ligands (TRAIL) has also been detected in cardiomyocytes similar to cancer cells [42, 43] , potentially attaining robust caspase-3 activation by invoking MOMP (type II cells, Fig. 1 ).
Are differentiated cardiomyocytes less likely to succumb to DOX-induced apoptosis?
Due to the discussed similarity in apoptosis pathways between cancer cells and cardiomyocytes, any strategy that aims to protect cardiomyocytes while killing cancer cells would aim to exploit differences in apoptosis likelihood rather than invoking distinct apoptosis pathways [44] [45] [46] . To this end, the Deshmukh lab has shown that differentiated rat cardiomyocytes, similar to primary neurons, have downregulated levels of the pro-apoptotic APAF-1 and increased expression of the anti-apoptotic XIAP compared to lessdifferentiated cells. In agreement with these changes, they indeed found a remarkable protection to caspase-3 activation and post-MOMP apoptosis when they added cytochrome c to their cell cultures. Interestingly, this protection was ablated by the XIAP-antagonist SMAC highlighting the balance of proand anti-apoptotic proteins in the post-MOMP pathway as decisive for this cardiomyocyte protection [47, 48] . From their biochemical study, a positive correlation between differentiation status and decreased apoptosis likelihood in response to DOX is hence expected. Evidence for this hypothesis comes from Konorev et al. who exposed three cell types with decreasing levels of maturity and differentiation, i.e., adult rat cardiomyocytes (ARCM), neonatal rat cardiomyocytes (NRCM), and rat embryonic H9C2 cardiomyoblasts to DOX [41] . To assess apoptosis, they used dedicated fluorogenic substrates for caspase-3 and caspase-9 activity. Their results demonstrated that ARCM had markedly lower caspase-3 and caspase-9 activity than both less-differentiated cell types. Likewise, mature NRCMs were more robust to apoptosis than H9C2 cardiomyoblast. Adding cytochrome c to permeabilised cells confirmed that this protection is mediated by apoptosis downstream to MOMP. In contrast, MOMP induction as evidenced by cytochrome c release revealed a trend that H9C2 and NRCM cells are more stable to apoptosis than the more differentiated ARCM, suggesting little or the absence of apoptosis protection due to differentiation upstream to MOMP. Decreased apoptosis susceptibility with cardiomyocyte maturity was also proposed in another study [49] . Comparing postnatal day 7 to day 21 myocardia and exposing them to the DOX, these authors confirmed that caspase-3 activity decreased by >20-fold and the amount of TUNEL positive cells was significantly reduced, most likely due to a significant reduction of APAF-1 and procaspase-9. However, despite the downregulation of the upstream, pro-apoptotic protein BAX during maturation, cytochrome c released as an indicator for MOMP in response to DOX exposure did not significantly differ between hearts of different maturity. From the above studies, we hence conclude that protection against DOXinduced apoptosis with increased differentiation status is exercised downstream to MOMP, while, in contrast, processes upstream to MOMP seem to be less protected or result in a greater susceptibility to MOMP upon differentiation and maturation.
Does DOX exposure change apoptosis likelihood of future somatic cardiomyocyte death?
Apart from acute cardiomyocyte apoptosis after DOX, a higher cell loss after cessation of treatment is possible if apoptosis likelihood increases after initial DOX exposure. Apoptosis may then occur gradually over time in response to somatic stimuli resulting in a continuously evolving compensatory cardiomyocyte hypertrophy and extracellular matrix adaptation to replace cell loss [20] . Evidence of increased apoptosis likelihood after DOX exposure is seen in studies of FAS-dependent apoptosis. Specifically, rat-derived embryonic cardiomyocytes, which are normally resistant to FAS-L-induced apoptosis [42] , may get sensitized to FAS-L when pre-exposed to DOX [50, 51] . Interestingly, DOX pre-exposure may also induce increased FAS-L released by rat-derived embryonic cardiomyocytes [42] , suggesting a DOX-sensitization dependent autocrine/ paracrine mechanism for cardiac apoptosis induction. Indeed, elevated FAS-L expression was found to be a risk factor for idiopathic DCM [52] , overload-induced DCM [53] , and for inducing apoptosis-mediated cardiac dilation and dysfunction after anti-viral therapy [54] , suggesting a role for FAS-L in developing a hypertrophic phenotype.
Besides changes in the secretion of paracrine factors, an increased apoptosis likelihood usually arises by shifting the balance between pro-and anti-apoptotic proteins. In the context of cancer cells, this mechanism was coined as apoptosis priming, aiming to explain why cancer cells are more susceptible to chemotherapy than normal cells. Specifically, proponents of the priming hypothesis such as the Letai group suggest that cancer cells increase their apoptosis likelihood in response to continuous somatic attack by the immune system [46, 55] , making them more likely than somatic cells to respond to cytotoxic chemotherapy. Indeed, we observe some parallels between cancer cells primed by somatic apoptosis [46, 56] and cardiomyocyte being exposed to (sub-lethal) DOX with respect to metabolic programming and apoptosis sensitization (Fig. 2) .
Evidence that DOX exposure can lead to apoptosis sensitization similar to cancer cell priming is presented in a study which found a decrease in mRNA expression of the anti-apoptotic BCL-2 and increase of pro-apoptotic BAX [57] . Likewise, in the aforementioned study of Zhang, an upregulation of mRNA transcripts was found for the pro-apoptotic gene APAF-1, BAX, and FAS-L after DOX exposure in mice with wild-type TOP-2β. Moreover, re-analyzing their Gene Expression Omnibus data set (GSE36239), we also found a transcriptional upregulation of XAF1, an inhibitor of the anti-apoptotic protein XIAP under the top 200 regulated genes in wild-type mice after DOX exposure. How this XAF-1 upregulation together with de-regulation of other apoptosis genes may lead to elevated apoptosis likelihood in presence of wild-type TOP-2β mice is illustrated by an in-house computational model of apoptosis signal transduction as given and described in Fig. 3 . Together, these findings suggest an apoptosis priming by DOX on a transcriptional level, making cardiomyocytes more likely to respond to further apoptosis stimuli [26] .
Similar to the case of cardiomyocyte differentiation, the change in apoptosis sensitivity after DOX pre-exposure seems to be different between pathways upstream and downstream of MOMP. Hence, increased protection against MOMP after DOX exposure, and hence a counter-priming, is indicated by an elevation of the anti-apoptotic protein BCL2 [24] , by an increase of BCL2/BAX protein ratio [58] and elevation of the anti-apoptotic gene ARC in the rat hearts [59, 60] . As most of these studies were performed in the whole hearts, further studies will reveal to what extent DOX primes or antiprimes cardiomyocytes towards pre-or post-MOMP apoptosis or to apoptosis susceptibility through cell death ligands.
Does DOX-induced MOMP functionally impair cardiomyocytes even in the absence of apoptosis?
The above studies suggest that cardiomyocytes acquire robustness against caspase activation upon differentiation. In contrast, the likelihood of MOMP induction following apoptosis stimuli seems to be unaffected by differentiation, or even higher than in undifferentiated cells [41, 47, 49] . Moreover, as outline above, MOMP may be induced by elevated FAS signaling after DOX. We therefore argue that protection against downstream apoptosis in differentiated cardiomyocytes in the presence of MOMP following acute DOX exposure may not be sufficient to guarantee viable, functional cells [61] .
The first argument is that cytochrome c release following MOMP deprives mitochondria of this important electron carrier in the mitochondrial respiration chain. This deprivation induces a bioenergetics crisis [58] consisting of lack of ATP production and failure of ionic homeostasis [62] which can directly lead to necrotic cell death in some cardiomyocytes and hence further cardiac injury. To avoid such necrosis, some cells have developed means to compensate the lack of functional mitochondria by a switch towards increased glycolysis, thereby maintaining ATP levels and ionic homeostasis after MOMP [31, 63] . Evidence for the presence of such a switch in Fig. 2 DOX exposure of cardiomyocyte as analogy to apoptosis priming in cancer cells. Analogies between cardiomyocytes exposed to DOX and cancer cells primed to apoptosis in the body. This hypothesis is linking toxic pre-exposure to apoptosis sensitization, metabolic remodeling, and differentiation status. Cardiomyocytes (left panel) exposed to DOX have a tendency to change from oxidative to glycolytic mechanism and to show a functional impairment [5, 64] , potentially also associated with a switch to fetal gene expression program [67, 90] . Likewise, while cardiomyocytes have acquired apoptosis resistance during differentiation [47] , DOX exposure may change the balance of pro-and anti-apoptotic proteins in favor of the latter [26, 91] or sensitize cardiomyocytes to cell death ligands [50] . As an analogy, cancer cells (right panel) are dedifferentiated cells arising from differentiated healthy tissue [44] . On a metabolic level, this de-differentiation is characterized by increased glycolysis and downregulation of mitochondrial ATP production, potentially by a shift from the mature to the fetal pyruvate-dependent kinase isoform [92, 93] . In addition, as cancer cells are continuously attacked by the immune system, the constant somatic stress makes them more sensitized to undergo chemotherapy-induced apoptosis. This sensitization was coined as apoptosis priming [46, 56] and was recently explained by the Prehn and Huber labs through systematic change in balance in favor of pro-apoptotic proteins using a system analysis [55] DOX-exposed cardiomyocytes comes from the observation of a shift from mitochondrial to glycolytic metabolism in the hearts of patients with DOX-induced or idiopathic DCM [3, 5, 64, 65] . The presence of such a glycolytic switch is further backed up by the fact that glucose transporter type I (GLUT1, the embryonic isoform [66] ) was elevated in rat hearts after DOX treatment and led to higher glucose import [67] to address the higher glucose demand by glycolysis. Together, these findings raise the possibility that DOX-induced MOMP can either kill cardiomyocytes by necrosis or invoke glycolytic remodeling. While this remodeling may keep cardiomyocytes viable, they may remain less functional as glycolysis may not sufficiently address the high energy demand in the heart [5, 23, 64, 65] .
We further argue that suppression of downstream apoptosis after MOMP is not sufficient to guarantee functional cardiomyocytes as, while being reduced, caspase-3 activity may not be completely abolished in differentiated Illustration of a how a computational signal transduction analysis can quantitatively assess the likelihood of apoptosis downstream to MOMP in the mouse hearts in the presence and absence of DOX pre-exposure. This analysis is based on our previously published computer model of post-MOMP apoptosis, APOPTO-CELL. As adaptation, we also included the pro-apoptotic protein XAF-1 which we modeled to act in the same way as SMAC, yet to be present initially in the cytosol instead of being released from the mitochondria [32, 69] . As input, we used gene expression data from Zhang [26] (GEO data set GSE36239). These authors performed an expression microarray analysis of heart tissue from wildtype-or TOP-2β −/− mice (inhibiting the canonical pathway of DOX) which they either subjected to PBS (control) or DOX. Hearts from three mice per condition were analyzed. a Analysis of expression profiles of apoptosis proteins required as input for APOPTO-CELL. Microarray read outs from GSE36239 were normalized to the average from the three PBSexposed wild-type mice. Results revealed that mice with functional TOP-2β and subjected to DOX had either significantly or nearly significantly (n = 3, *p < 0.05, two-sided t test) increased XAF-1 levels compared to those mice where DOX was either not applied or its pathway was assumed to be non-functional (TOP-2β −/−). A similar expression trend, albeit showing no significance, was observed for the pro-apoptotic protein APAF-1. This trend was also present at much smaller extent in the pro-apoptotic protein caspase-3. Other proteins relevant to APOPTO-CELL did not show an observable trend with expression differences between groups lower than a factor 1.3 and were hence not shown. b Analysis pipeline to study change in apoptosis likelihood after wildtype-and TOP-2β −/− mice have been exposed to PBS or DOX. As absolute protein expressions are needed as model input, we assumed a set point for the relevant proteins (caspase-3 100 nM, caspase-9 10 nM, XIAP 500 mN, APAF-1 100 nM, SMAC 100 nM, XAF-1 100 nM). This set point was considered to describe the average expressions in the PBSexposed group of three wild-type mice. From this, we used the changes in expression levels for each group (see panel a) and for each mouse in the group to estimate sample-individual profiles for above proteins. Using this as model input, APOPTO-CELL calculated the likelihood of cell death after 300 min which is an estimate how PBS and DOX preexposed mice would react to further apoptosis stimuli. As a result, mice with functional TOP-2β and exposed to DOX were statistically significantly primed to apoptosis compared to such which were either not exposed to DOX or where its canonical pathway was not functional (TOP-2β−/−) cardiomyocytes after DOX exposure. Importantly, mild, nonlethal caspase-3 activity can lead to structural remodeling in large cells [68] . Elegantly shown by single cell imaging and quantitative system biology studies of apoptosis, sub-lethal caspase-3 activity can arise when tipping the balance for expression of proteins relevant in the post-MOMP pathway from proapoptotic to anti-apoptotic ones [32, 69, 70] . Indeed, apoptosome-dependent, sub-lethal caspase activity was recently suggested to be essential for cardiomyocyte hypertrophic remodeling [71] . Specifically, using hypertrophy-inducing agonists, the authors demonstrated that caspase-9 and caspase-3 were activated in the cardiomyocytes, yet to an extent that was too low to induce apoptosis. Cardiomyocyte hypertrophy was ablated after either blocking caspase-9 and caspase-3. Likewise, in the rat myocardium, the hypertrophic phenotype after hypertrophyinducing agonists was attenuated when caspase-3 was blocked. Most interestingly, activating caspase-3 with targeted pharmacologic activators (PAC-1 compounds) was sufficient to induce cardiomyocyte hypertrophy in the absence of other hypertrophy-inducing stimuli. These findings are consistent with previous findings of a relation between incomplete apoptosis, sub-lethal caspase-3 activity, and non-functional cardiomyocytes (Bzombie cells^) that were found in patients with a DCM phenotype [72] . We therefore propose that structural remodeling of cardiomyocytes may partly be a consequence of sub-lethal caspase activation following acute DOX treatment; as differentiated, cardiomyocytes show attenuated, but potentially not completely blocked caspase-3 activation after MOMP.
The apoptosis hypothesis relevant to other pathways in DOX-induced injury
If apoptosis is the dominant regulator of DOX-induced DCM remains controversial. Nevertheless, apoptosis has also been implicated in most of the concurring models of DOX-induced DCM. To this end, increased production of ROS is considered to be a major inducer of cardiac malignancy following DOX [12] . ROS is usually thought to be elevated in cardiomyocyte by DOX binding to cardiolipin at the inner mitochondrial membrane, impairing mitochondrial respiration [73] . ROS after DOX exposure can also be induced by altering endothelial nitric oxidase signaling leading further to reduced production of the cardiac vasodilator NO [74] . Both increased ROS and lack of NO can hence directly impair the myocardium and heart muscle compliance even in the absence of apoptosis [75] . Besides this direct impairment of cardiac function, ROS-induced oxidative stress can also induce cardiomyocyte apoptosis [76] . Oxidative stress has been shown to transcriptionally alter BCL-2 family protein expression, leading to MOMP and cytochrome c release [12, 77] . Hence, any DOX-dependent apoptosis sensitization as proposed here may exacerbate ROS-induced impairment of cardiac viability.
Conversely, it is possible that apoptosis sensitization after DOX exposure results from oxidative stress-induced transcription of pro-apoptotic proteins [78] .
The interplay between protective autophagocytic processes and apoptosis has also been suggested to be a regulator of DOX-induced injury [13, 79] , potentially allowing the alleviation of metabolic stress after MOMP or after other ROS-induced impairment of mitochondria [73] . Indeed, upregulation of the major autophagy inducer Beclin-1 has been observed in cardiomyocytes in a time and dose-dependent manner after DOX exposure [79] . Importantly, as Beclin-1 is a substrate of caspase-3, the downregulation of caspase-3 activity in differentiated cardiomyocytes may guarantee execution of autophagy, therefore alleviating cellular metabolic injury. Nevertheless, activity of autophagocytation of mitochondria (mitophagy), which may become damaged after DOX-induced MOMP, has been also shown to be detrimental. To this end, recent literature indications point to a positive correlation between mitophagy and sensitization to DOX-injury, although the causative role of mitophagy remains unknown [80, 81] .
Limitations of current studies on the effect of DOX exposure
Our review is dedicated to the relevance of apoptosis signaling in DOX-induced DCM with a focus on how cardiomyocyte sensitivity to apoptosis depends on maturation and differentiation state and to previous exposure to DOX. We have therefore limited our report to the analysis of whole heart tissue and dedicated cardiomyocyte studies. Yet, DOX susceptibility to apoptosis in other relevant cells such as in bovine aortic endothelial cells were also reported and apoptosis may act in a p53-dependent and independent way [82] . Consistent with our focus on the non-proliferating cardiomyocytes, we have further not discussed the effect of DOX-induced submaximal caspase activation on cellular hyper-proliferation [83] . Nevertheless, caspase activity has been shown to be relevant for differentiation of skeletal myoblasts [84] . Hence, submaximal protease activity following DOX exposure may stimulate differentiation and aberrant proliferation of multipotent cardiac progenitor cells, cardiac stem cells, or of cardiomyocytes de-differentiated by DOX, and hence contribute either to malignant cardiac re-organization or alternatively induce cardiac regeneration [85] .
Conclusion and outlook
We here discussed DOX-induced DCM from the perspective of how cardiomyocyte sensitivity to apoptosis depends on differentiation state and previous exposure to DOX. Yet, the relation between differentiation, DOX exposure, and apoptosis likelihood warrants further investigation at a cardiomyocyte level. This may be done by differentiating H9C2 cardiomyoblast [86] , cardiac progenitor cells, or inducible pluripotent stem cells and by pre-exposing the differentiated cells to mild DOX that would not kill the cells, but rather alter their composition of cell death proteins.
We further note that changes of protein expressions relevant to apoptosis can be subtle and that regulation of proteins in response to differentiation and DOX pre-exposure must be studied in their interplay. As such, the studies of Konorev [41] and Potts [47] agreed that post-MOMP apoptosis is markedly reduced upon cell maturation but attributed this effect to different protein regulation patterns. We therefore propose computational signal transduction models to study how combined changes in protein expression levels translate to cardiomyocyte vulnerability to apoptosis. Figure 3 illustrates how such models can quantitatively assess apoptosis likelihood in the presence and absence of DOX pre-exposure using expression data relevant to apoptosis proteins. Our model illustrates that, while regulation patterns of genes and proteins may be more diffuse between subjects and conditions, their combined action in a defined pathway can lead to a clearer regulation pattern of apoptosis. Indeed, with such quantitative signal transduction models, we were previously able to predict patient specific susceptibility to chemotherapy [32, 45, 55, 87, 88] . It is therefore expected that these models in combination with biomolecular studies that investigate molecular mediators of apoptosis can further help to identify patients more vulnerable to DOX-induced cardiac apoptosis and DCM. These computer models may further predict targets for secondary treatments such as dexrazoan [89] that reduce cardiomyocyte apoptosis after DOX, while leaving DOX's action in cancer cells intact.
